The Patent Finder

Orthopeutics Group, LLC

Also on record
Records under this name other than patents Orthopeutics Group, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Orthopeutics Group, LLC

PatentTitleStatus Expires Confidence
US 10,278,947Crosslinker Enhanced Repair of Connective Tissues
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,283,322Formulations for nonsurgical exogenous crosslink therapy
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,198,248Formulations for nonsurgical exogenous crosslink therapy
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,084,772Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,119,599Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
Formerly held
Term ended
Term ended Apr 1, 2025 · From the USPTO record
Term endedTerm ended Apr 1, 2025From the USPTO record
US 7,435,722Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
Formerly held
Term ended
Term ended Jan 19, 2025 · From the USPTO record
Term endedTerm ended Jan 19, 2025From the USPTO record
US 9,101,602Use of Non-Toxic Crosslinking Reagents to Improve Fatigue Resistance and Reduce Mechanical Degradation of Intervertebral Disc and Other Collagenous Tissues
Formerly held
Term ended
Ended no later than Mar 16, 2024 · Medium confidence
Term endedEnded no later than Mar 16, 2024Medium confidence
US 8,450,276Non-Toxic Crosslinking Reagents to Resist Curve Progression in Scoliosis and Increase Disc Permeability
Formerly held
Term ended
Ended no later than Aug 1, 2023 · Low confidence
Term endedEnded no later than Aug 1, 2023Low confidence
US 8,211,938Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
Formerly held
Term ended
Term ended May 7, 2023 · From the USPTO record
Term endedTerm ended May 7, 2023From the USPTO record
US 9,192,507Tissue crosslinking for treatment of snoring and obstructive sleep apnea
Formerly held
Term ended
Term ended Jan 6, 2023 · From the USPTO record
Term endedTerm ended Jan 6, 2023From the USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited